Utilization of glucocorticoids among White and Black patients with systemic lupus erythematosus: Observations from the enrollment visit of a prospective registry

Abstract

Background

Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated with worse health outcomes among patients with SLE. We sought to quantify chronic glucocorticoid use among Black and White patients with SLE within a prospective registry.

Methods

Using enrollment data from a registry at a large academic institution, we compared glucocorticoid use among Black and White patients with SLE. Multivariable logistic regression of race and glucocorticoid use was performed, adjusting for covariates exhibiting a bivariate association with glucocorticoids at significance level p < 0.10.

Results

114 White participants (mean age 45; standard deviation (SD) 15) and 59 Black participants (mean age 42; SD 14) were analyzed. White participants had mean SLEDAI-2K score of 3.7 (SD 5.2). Black participants had mean SLEDAI-2K scores of 6.3 (SD 6.0). Among Black participants, 43 (72%) utilized glucocorticoids compared to White participants 39 (34%) (unadjusted odds ratio (OR) 5.17; 95% confidence interval (CI) 2.59–10.33). We did not observe differences between unadjusted hydroxychloroquine (OR 0.69; 95% CI 0.28–1.65) or conventional disease-modifying anti-rheumatic drug (cDMARD) (OR 1.07; 95% CI 0.57–2.01) utilization among Black and White participants. SLEDAI-2K, disability, recent hospitalization, and past or present hydroxychloroquine or cDMARD use were included in a logistic regression model. Adjusting for covariates, Black participants were more likely to be on glucocorticoids (adjusted OR 5.69; 95% CI 2.17–14.96); p = 0.0004).

Conclusion

Adjusting for disease activity and other medications, Black patients had more exposure to chronic glucocorticoids than White patients in the Cleveland Clinic SLE registry. These patients may face increased glucocorticoid-related morbidity, which could contribute significantly to long-term health outcomes and utilization of health care resources. Future research in larger, more diverse registries should be conducted to further characterize patterns of glucocorticoid use.

Keywords

Systemic lupus erythematosus corticosteroids health disparities

Get full access to this article

View all access options for this article.

References

Drenkard

Lim

. Update on lupus epidemiology: Advancing health disparities research through the study of minority populations. Curr Opin Rheumatol 2019; 31: 689–696.

Chae

Martz

Fuller-Rowell

, et al. Racial discrimination, disease activity, and organ damage: The black women’s experiences living with lupus (BeWELL) study. Am J Epidemiol 2019; 188: 1434–1443.

Karlson

Liang

Eaton

, et al. A randomized clinical trial of a psychoeducational intervention to improve outcomes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 1832–1841.

Feldman

Yazdany

Guan

, et al. Medication nonadherence is associated with increased subsequent acute care utilization among medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2015; 67: 1712–1721.

Feldman

Williams

, et al. Patterns and predictors of recurrent acute care use among Medicaid beneficiaries with systemic lupus erythematosus. Semin Arthritis Rheum 2020; 50: 1428–1436. DOI: 10.1016/j.semarthrit.2020.02.012

Apostolopoulos

Kandane-Rathnayake

Louthrenoo

, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: A multicentre cohort study. Lancet Rheumatol 2020; 2: e24–e30.

Petri

Orbai

A-M

Alarcón

, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

Aringer

Costenbader

Daikh

, et al. EULAR/ACR classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71: 1400–1412.

Harris

Taylor

Thielke

, et al. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377–381.

10.

Gladman

Ibañez

Urowitz

. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.

11.

VanderWeele

Robinson

. On causal interpretation of race in regressions adjusting for confounding and mediating variables. Epidemiology 2014; 25: 473–484.

12.

Maldonado

Greenland

. Simulation study of confounder-selection strategies. Am J Epidemiol 1993; 138: 923–936.

13.

Yazdany

Tonner

Schmajuk

, et al. Receipt of glucocorticoid monotherapy among medicare beneficiaries with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66: 1447–1455.

14.

Chu

L-H

Portugal

Kawatkar

, et al. Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California medicaid rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2013; 65: 299–303.

15.

Wallace

Lin

Kamdar

, et al. Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. Semin Arthritis Rheum 2020; 50: 228–236.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.06 MB